APYX:NSD-Apyx Medical Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 12.49

Change

+0.68 (+5.76)%

Market Cap

USD 0.39B

Volume

0.10M

Avg Analyst Target

USD 14.00 (+12.09%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

-1.87 (-0.26%)

USD56.71B 124.35 55.99
PODD Insulet Corporation

-1.40 (-0.48%)

USD20.01B 2,208.27 244.52
ABMD Abiomed Inc

-0.25 (-0.07%)

USD15.91B 103.67 53.06
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-0.29 (-0.34%)

USD12.64B 81.79 28.22
SWAV ShockWave Medical Inc

-5.12 (-2.25%)

USD8.00B N/A N/A
TNDM Tandem Diabetes Care Inc

-1.72 (-1.37%)

USD7.91B 1,218.35 239.94
INMD InMode Ltd

+5.43 (+3.17%)

USD6.53B 57.19 40.15
IART Integra LifeSciences Holdings ..

-0.15 (-0.21%)

USD6.12B 29.96 19.16
LIVN LivaNova PLC

-0.47 (-0.57%)

USD4.37B 77.40 N/A

ETFs Containing APYX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 73.47% 78% C+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 73.47% 78% C+ 91% A-
Trailing 12 Months  
Capital Gain 162.95% 82% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 162.95% 82% B- 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.62% 43% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.62% 43% F 65% D
Risk Return Profile  
Volatility (Standard Deviation) 59.48% 55% F 30% F
Risk Adjusted Return 34.68% 52% F 50% F
Market Capitalization 0.39B 52% F 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.30 64% D 86% B
Price/Book Ratio 6.65 32% F 21% F
Price / Cash Flow Ratio -24.29 69% D+ 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -22.84% 54% F 39% F
Return on Invested Capital -18.60% 59% F 29% F
Return on Assets -12.90% 44% F 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.09 19% F 17% F
Short Percent 2.13% 72% C- 58% F
Beta 0.91 64% D 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector